donepezil has been researched along with Cognitive Decline in 94 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "APOE-ɛ4 and BCHE-K* positive subjects display an earlier age of onset of AD, an accelerated cognitive decline and a greater cognitive benefits to donepezil therapy." | 9.22 | Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. ( De Beaumont, L; Dea, D; Lamarre-Théroux, L; Pelleieux, S; Poirier, J, 2016) |
| "Over the 48-week treatment period, donepezil combined NBP group had slower cognitive decline and better activities of daily living in patients with mild to moderate AD." | 8.02 | Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study. ( Gao, F; Guo, X; Liu, J; Lu, W; Ma, L; Qu, Q; Quan, Q; Su, H; Wang, J; Zhang, H, 2021) |
| "We report the case of a 74-year-old woman who presented with amnesia and positive serum anticholinergic activity (SAA), which disappeared after treatment with the cholinesterase inhibitor donepezil for 1 year." | 7.79 | Donepezil abolishes anticholinergic activity in a patient with amnesia. ( Akita, R; Hachisu, M; Hori, K; Konishi, K; Minegishi, G; Oshio, T; Tanaka, H; Tani, M; Tomioka, H; Yokoyama, S, 2013) |
| "Colitis was evoked by a single transrectal injection of 1 ml of 4 % acetic acid." | 5.91 | Donepezil halts acetic acid-induced experimental colitis in rats and its associated cognitive impairment through regulating inflammatory/oxidative/apoptotic cascades: An add-on to its anti-dementia activity. ( Ahmed, KA; Elbaz, EM; Essam, RM; Safwat, MH, 2023) |
| "Donepezil-treated MCI individuals showed slower atrophy rates compared to the placebo group, but only if they belonged to the minimal atrophy or hippocampal-sparing subtypes." | 5.69 | Differential response to donepezil in MRI subtypes of mild cognitive impairment. ( Cavedo, E; Diaz-Galvan, P; Dubois, B; Ferreira, D; Grothe, MJ; Hampel, H; Kantarci, K; Lista, S; Lorenzon, G; Mårtensson, G; Mohanty, R; Vergallo, A; Westman, E, 2023) |
| "The authors conducted a delayed-start study of donepezil for cognitive decline in non-demented PD patients." | 5.41 | Early-start ( Kiyohara, K; Kohsaka, M; Oeda, T; Park, K; Sawada, H; Tomita, S; Umemura, A; Yamamoto, K, 2021) |
| "We determined the value of hippocampus (Hp) and basal forebrain (BF) volumes for predicting cognitive decline and treatment response in a double-blind, randomized, placebo-controlled phase 4 trial at 28 academic centers (France) in patients with amnestic mild cognitive impairment (MCI) receiving Donepezil 10 mg daily or placebo over 12 months, and 6 months open label follow-up." | 5.22 | Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. ( Bakardjian, H; Cavedo, E; Chupin, M; Colliot, O; Dormont, D; Dubois, B; Galluzzi, S; Grothe, MJ; Hampel, H; Lista, S; Teipel, SJ, 2016) |
| " Studies in early radiotherapy treatment phase (five studies) Pharmacological studies in the "early radiotherapy treatment phase" were designed to prevent or ameliorate cognitive deficits and included drugs used in dementia (memantine) and fatigue (d-threo-methylphenidate hydrochloride)." | 5.22 | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. ( Brown, PD; Day, J; Gehring, K; Grosshans, D; Kirkman, MA; Li, J; Taphoorn, M; Zienius, K, 2022) |
| "APOE-ɛ4 and BCHE-K* positive subjects display an earlier age of onset of AD, an accelerated cognitive decline and a greater cognitive benefits to donepezil therapy." | 5.22 | Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. ( De Beaumont, L; Dea, D; Lamarre-Théroux, L; Pelleieux, S; Poirier, J, 2016) |
| "Over the 48-week treatment period, donepezil combined NBP group had slower cognitive decline and better activities of daily living in patients with mild to moderate AD." | 4.02 | Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study. ( Gao, F; Guo, X; Liu, J; Lu, W; Ma, L; Qu, Q; Quan, Q; Su, H; Wang, J; Zhang, H, 2021) |
| "BACKGROUND The aim of this study was to investigate the effects of oxygen and cholinesterase inhibitor (donepezil) therapy on dementia in patients with age-exacerbated chronic obstructive pulmonary disease (COPD) in China's northwestern high-altitude area." | 3.88 | Epidemiology of Dementia in Elderly Chronic Obstructive Pulmonary Disease Patients Living in China's Northwestern High-Elevation Area. ( Li, H; Mei, L; Wang, D; Wang, M; Wu, S; Zhang, H, 2018) |
| "BChE-K polymorphisms are associated with deleterious changes in cognitive decline in MCI patients treated with donepezil for 3 years." | 3.85 | Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. ( Aisen, PS; Apostolova, LG; Chen, L; Li, X; Rissman, RA; Rotter, JI; Sokolow, S; Taylor, KD, 2017) |
| "We report the case of a 74-year-old woman who presented with amnesia and positive serum anticholinergic activity (SAA), which disappeared after treatment with the cholinesterase inhibitor donepezil for 1 year." | 3.79 | Donepezil abolishes anticholinergic activity in a patient with amnesia. ( Akita, R; Hachisu, M; Hori, K; Konishi, K; Minegishi, G; Oshio, T; Tanaka, H; Tani, M; Tomioka, H; Yokoyama, S, 2013) |
| " No significant, non-flat dose-response relationship was detected for the primary endpoint (adjusted p-value > 0." | 3.30 | Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer's dementia: a randomized controlled trial. ( Blahova, Z; Garcia, M; Jessen, F; Wunderlich, G, 2023) |
| "The network meta-analysis was used to evaluate the efficacy of acupuncture combined with other therapies in the treatment of post stroke cognitive impairment (PSCI)." | 3.01 | The efficacy of acupuncture combined with other therapies in post stroke cognitive impairment: A network meta-analysis. ( Dong, X; Huo, H; Li, S; Liu, Y; Wang, D; Wang, Y; Zhang, H; Zhang, Y; Zhao, D, 2023) |
| "There was no association with accidental injuries or fractures." | 3.01 | Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis. ( Ahuja, M; Gabor, C; Karimi, A; Lee, J; Lewis, K; Patterson, C; Reppas-Rindlisbacher, C; Siddhpuria, S; Sood, E; Wong, E, 2023) |
| "Donepezil treatment improved dual-task gait speed and DTC in elderly patients with MCI." | 2.90 | Donepezil for gait and falls in mild cognitive impairment: a randomized controlled trial. ( Bherer, L; Borrie, M; Chertkow, H; Fraser, S; Montero-Odasso, M; Muir-Hunter, SW; Sarquis-Adamson, Y; Speechley, M; Vanderhaeghe, L; Wells, J; Zou, GY, 2019) |
| "Late mild cognitive impairment patients had significantly worse ADAS-Cog (P < ." | 2.87 | Clinical and radiological characteristics of early versus late mild cognitive impairment in patients with comorbid depressive disorder. ( Ciovacco, MW; D'Antonio, K; Devanand, DP; Doraiswamy, PM; Garcon, E; Motter, JN; Pelton, GH; Petrella, JR; Pimontel, MA; Rushia, SN; Sneed, JR, 2018) |
| "Donepezil was associated with more adverse effects than placebo." | 2.87 | Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial. ( Andrews, H; Beyer, JL; Ciarleglio, A; Ciovacco, M; D'Antonio, K; Devanand, DP; Doraiswamy, PM; Lunsford, J; Pelton, GH; Petrella, JR; Scodes, J; Sneed, J, 2018) |
| " However, there is no trend of significantly delaying the progression of the disease, and it is easy to lead to the occurrence of adverse reactions." | 2.82 | Efficacy and safety of donepezil for mild cognitive impairment: A systematic review and meta-analysis. ( Lian, S; Zhang, X; Zhang, Y; Zhao, Q, 2022) |
| "Donepezil treatment significantly enhanced the response time for face and scene memory probes when compared to the placebo group." | 2.78 | Cholinergic enhancement of functional networks in older adults with mild cognitive impairment. ( Berry, AS; Boccanfuso, J; Compagnone, M; Gazzaley, A; Greenhouse, I; Johnson, JK; Pa, J; Rubens, MT, 2013) |
| "Cognitive dysfunction is common in Parkinson's disease (PD) and predicts poor clinical outcomes." | 2.66 | Approach to Cognitive Impairment in Parkinson's Disease. ( Aldridge, GM; Anderson, SW; Narayanan, NS; Uc, EY; Zhang, Q, 2020) |
| "Pharmacotherapeutic approaches for cancer therapy-induced cognitive symptoms include CNS stimulants (eg, methylphenidate and modafinil), medications used in patients with memory impairment (eg, donepezil, memantine, and ginkgo biloba), and bone marrow supporting agents (eg, erythropoietin)." | 2.61 | Pharmacologic management of cognitive impairment induced by cancer therapy. ( Dietrich, J; Karschnia, P; Parsons, MW, 2019) |
| "Many patients with brain cancer experience cognitive problems." | 2.61 | Interventions for cognitive problems in adults with brain cancer: A narrative review. ( Gehring, K; Klaver, KM; Schagen, SB; Sitskoorn, MM; van Lonkhuizen, PJC; Wefel, JS, 2019) |
| " Based on these studies, donepezil has been shown to be effective and safe in Chinese AD patients and may impact AD biomarkers, such as hippocampal atrophy, Aβ, and tau." | 2.58 | Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients. ( Gordon, ML; Zhang, N, 2018) |
| "Antipsychotic treatment for dementia alleviates cognitive dysfunction less effectively than does symptomatic treatment." | 2.58 | The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis. ( Chang, YC; Perng, CH; Tzang, RF, 2018) |
| "Parkinson's disease is the second most frequent neurodegenerative disorder." | 2.52 | Cognitive impairment in Parkinson's disease. ( Ransmayr, G, 2015) |
| "Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction, commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic leukemia (ALL), or tumors involving the head and neck." | 2.50 | Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. ( Castellino, SM; Lange, BJ; Ullrich, NJ; Whelen, MJ, 2014) |
| "In randomized clinical trials, adverse events (AEs) are reported for the drug under evaluation and compared with the placebo group." | 2.48 | A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment. ( Amanzio, M; Benedetti, F; Vase, L, 2012) |
| "The pathogenesis of Alzheimer's disease (AD) is complex, resulting in unsatisfactory effects of single-target therapeutic drugs." | 2.44 | Ginsenoside RK1 improves cognitive impairments and pathological changes in Alzheimer's disease via stimulation of the AMPK/Nrf2 signaling pathway. ( Li, A; Li, L; Liang, G; Ren, J; She, L; Sun, J; Wang, W; Wu, H; Xiong, L; Zhao, X, 2024) |
| "Colitis was evoked by a single transrectal injection of 1 ml of 4 % acetic acid." | 1.91 | Donepezil halts acetic acid-induced experimental colitis in rats and its associated cognitive impairment through regulating inflammatory/oxidative/apoptotic cascades: An add-on to its anti-dementia activity. ( Ahmed, KA; Elbaz, EM; Essam, RM; Safwat, MH, 2023) |
| "All 8 patients had mild cognitive impairment including 6 with amnestic, multidomain impairment." | 1.72 | Effectiveness of an integrative medicine approach to improve cognitive dysfunction and dementia: An observational study. ( Kang, H; Kim, DY; Kim, KK; Kim, MG; Koo, BS; Lee, JH; Shin, HW, 2022) |
| "Cardiovascular complications in Alzheimer's disease (AD) patients can occur years to decades prior to the onset of clinical symptoms of the disease." | 1.62 | Donepezil improves vascular function in a mouse model of Alzheimer's disease. ( Antonioli, L; Baldacci, F; Bernardini, N; Blandizzi, C; D'Antongiovanni, V; Duranti, E; Fornai, M; Masi, S; Pellegrini, C; Taddei, S; Virdis, A, 2021) |
| "1." | 1.56 | Reduced systemic exposure and brain uptake of donepezil in rats with scopolamine-induced cognitive impairment. ( Ren, T; Wang, Q; Yang, M; Zhang, Y; Zhao, J; Zuo, Z, 2020) |
| "In patients with mild cognitive impairment (MCI) treated prospectively with donepezil, a CheI, for 52 weeks, to determine if 1) acute decline in odor identification ability with anticholinergic challenge can predict cognitive improvement, and 2) change in odor identification over 8 weeks can predict cognitive improvement." | 1.56 | Odor Identification Impairment and Change with Cholinesterase Inhibitor Treatment in Mild Cognitive Impairment. ( Andrews, H; Choi, J; Chunga, RE; Cohen, H; Devanand, DP; Huey, ED; Liu, X; Pelton, GH; Schofield, PW; Stern, Y, 2020) |
| "Late-onset Alzheimer's disease (AD) differs substantially from early-onset AD." | 1.51 | rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine. ( Iyo, M; Oda, Y; Okubo, T; Sato, K; Shirayama, Y; Takahashi, M; Yoshino, K, 2019) |
| "The diverse nature of Alzheimer's disease (AD) has prompted researchers to develop multi-functional agents." | 1.51 | Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. ( Choubey, PK; Krishnamurthy, S; Prajapati, SK; Seth, A; Sharma, P; Shrivastava, SK; Tripathi, A; Tripathi, MK; Tripathi, PN, 2019) |
| "Donepezil was started at 5 mg daily, increased to 10 mg daily if tolerated, and then the dose was kept constant for 52 weeks." | 1.46 | Change in Odor Identification Impairment is Associated with Improvement with Cholinesterase Inhibitor Treatment in Mild Cognitive Impairment. ( Andrews, H; Bell, K; Chunga, RE; Ciarleglio, A; Devanand, DP; Huey, ED; Lentz, C; Pelton, GH; Schofield, PW; Scodes, JM; Stern, Y, 2017) |
| "The effects of AD-35 on cognitive impairments and neuroinflammatory changes caused by intracerebroventricular injection of Aβ25-35 were studied in rats." | 1.46 | Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease. ( Cai, J; Feng, N; Feng, R; Gong, Y; Li, J; Li, L; Liu, L; Peng, Y; Wang, L; Wang, X; Xu, S; Zhao, X, 2017) |
| "Donepezil was suspected to have induced the new symptoms and was discontinued." | 1.40 | Donepezil-induced mania. ( Leung, JG, 2014) |
| "Using presently available clinical evidence, this exploratory study illustrates that genetic testing combined with preventive donepezil treatment for AMCI patients may be economically attractive." | 1.38 | Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine. ( Beca, J; Black, S; Djalalov, S; Hoch, JS; Moretti, M; Musa, Z; Saposnik, G; Siminovitch, K; Yong, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 50 (53.19) | 24.3611 |
| 2020's | 44 (46.81) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, YX | 1 |
| Wang, H | 1 |
| Li, XK | 1 |
| Dong, SN | 1 |
| Liu, WW | 1 |
| Gong, Q | 1 |
| Wang, TD | 1 |
| Tang, Y | 1 |
| Zhu, J | 1 |
| Li, J | 6 |
| Zhang, HY | 1 |
| Mao, F | 1 |
| Piplani, P | 1 |
| Jain, A | 1 |
| Devi, D | 1 |
| Sharma, A | 1 |
| Silakari, P | 1 |
| Stachel, SJ | 1 |
| Egbertson, MS | 1 |
| Wai, J | 1 |
| Machacek, M | 1 |
| Toolan, DM | 1 |
| Swestock, J | 1 |
| Eddins, DM | 1 |
| Puri, V | 1 |
| McGaughey, G | 1 |
| Su, HP | 1 |
| Perlow, D | 1 |
| Wang, D | 3 |
| Ma, L | 2 |
| Parthasarathy, G | 1 |
| Reid, JC | 1 |
| Abeywickrema, PD | 1 |
| Smith, SM | 1 |
| Uslaner, JM | 1 |
| Sharma, P | 4 |
| Tripathi, A | 2 |
| Tripathi, PN | 3 |
| Prajapati, SK | 2 |
| Seth, A | 3 |
| Tripathi, MK | 2 |
| Srivastava, P | 2 |
| Tiwari, V | 1 |
| Krishnamurthy, S | 2 |
| Shrivastava, SK | 3 |
| Hogendorf, AS | 1 |
| Hogendorf, A | 1 |
| Kurczab, R | 1 |
| Kalinowska-Tłuścik, J | 1 |
| Popik, P | 1 |
| Nikiforuk, A | 1 |
| Krawczyk, M | 1 |
| Satała, G | 1 |
| Lenda, T | 1 |
| Knutelska, J | 1 |
| Bugno, R | 1 |
| Staroń, J | 1 |
| Pietruś, W | 1 |
| Matłoka, M | 1 |
| Dubiel, K | 1 |
| Moszczyński-Pętkowski, R | 1 |
| Pieczykolan, J | 1 |
| Wieczorek, M | 1 |
| Pilarski, B | 1 |
| Zajdel, P | 1 |
| Bojarski, AJ | 1 |
| Choubey, PK | 1 |
| Huang, XF | 1 |
| Dong, YH | 1 |
| Wang, JH | 1 |
| Ke, HM | 1 |
| Song, GQ | 1 |
| Xu, DF | 1 |
| Singh, YP | 1 |
| Tej, GNVC | 1 |
| Pandey, A | 1 |
| Priya, K | 1 |
| Pandey, P | 1 |
| Shankar, G | 1 |
| Nayak, PK | 1 |
| Rai, G | 1 |
| Chittiboyina, AG | 1 |
| Doerksen, RJ | 1 |
| Vishwakarma, S | 1 |
| Modi, G | 1 |
| Li, Q | 1 |
| Chen, Y | 3 |
| Xing, S | 1 |
| Liao, Q | 1 |
| Xiong, B | 1 |
| Wang, Y | 3 |
| Lu, W | 2 |
| He, S | 1 |
| Feng, F | 1 |
| Liu, W | 1 |
| Sun, H | 1 |
| Beversdorf, DQ | 1 |
| Nagaraja, HN | 1 |
| Bornstein, RA | 1 |
| Scharre, DW | 1 |
| Pisani, S | 1 |
| Mueller, C | 1 |
| Huntley, J | 1 |
| Aarsland, D | 1 |
| Kempton, MJ | 1 |
| Zhu, H | 1 |
| Cong, L | 1 |
| Chen, S | 1 |
| Chen, L | 2 |
| Huang, Z | 1 |
| Zhou, J | 1 |
| Xiao, J | 1 |
| Huang, Y | 1 |
| Su, D | 1 |
| Washida, K | 1 |
| Kitajima, E | 1 |
| Tanaka, T | 1 |
| Ikeda, S | 1 |
| Chiba, T | 1 |
| Noda, K | 1 |
| Yoshimoto, T | 1 |
| Fukuma, K | 1 |
| Saito, S | 1 |
| Ihara, M | 1 |
| Morris, JK | 1 |
| McCoin, CS | 1 |
| Fuller, KN | 1 |
| John, CS | 1 |
| Wilkins, HM | 1 |
| Green, ZD | 1 |
| Wang, X | 2 |
| Burns, JM | 1 |
| Vidoni, ED | 1 |
| Mahnken, JD | 1 |
| Shankar, K | 1 |
| Swerdlow, RH | 1 |
| Thyfault, JP | 1 |
| Pellegrini, C | 1 |
| D'Antongiovanni, V | 1 |
| Fornai, M | 1 |
| Duranti, E | 1 |
| Baldacci, F | 1 |
| Bernardini, N | 1 |
| Taddei, S | 1 |
| Virdis, A | 1 |
| Blandizzi, C | 1 |
| Masi, S | 1 |
| Antonioli, L | 1 |
| Zheng, C | 1 |
| Ge, Q | 1 |
| Yan, S | 1 |
| Paranjpe, MD | 1 |
| Hu, S | 1 |
| Zhou, Y | 1 |
| Shi, X | 1 |
| Ren, G | 1 |
| Cui, Y | 1 |
| Xu, Z | 1 |
| Zhang, X | 1 |
| Lian, S | 1 |
| Zhang, Y | 3 |
| Zhao, Q | 1 |
| Rotstein, A | 1 |
| Levine, SZ | 1 |
| Samara, M | 1 |
| Yoshida, K | 1 |
| Goldberg, Y | 1 |
| Cipriani, A | 1 |
| Iwatsubo, T | 1 |
| Leucht, S | 1 |
| Furukawa, TA | 1 |
| Spangenburg, EE | 1 |
| Arif, M | 1 |
| Rauf, K | 1 |
| Rehman, NU | 1 |
| Tokhi, A | 1 |
| Ikram, M | 1 |
| Sewell, RD | 1 |
| Alvarez, XA | 1 |
| Winston, CN | 1 |
| Barlow, JW | 1 |
| Sarsoza, FM | 1 |
| Alvarez, I | 1 |
| Aleixandre, M | 1 |
| Linares, C | 1 |
| García-Fantini, M | 1 |
| Kastberger, B | 1 |
| Winter, S | 1 |
| Rissman, RA | 3 |
| Kim, KW | 1 |
| Wang, Q | 3 |
| Koo, SH | 1 |
| Shin, BS | 1 |
| Lee, JH | 1 |
| Kim, MG | 1 |
| Kim, DY | 1 |
| Shin, HW | 1 |
| Kang, H | 1 |
| Koo, BS | 1 |
| Kim, KK | 1 |
| Vidal, B | 1 |
| Pereira, M | 1 |
| Valdebenito, M | 1 |
| Vidal, L | 1 |
| Mouthon, F | 1 |
| Zimmer, L | 1 |
| Charvériat, M | 1 |
| Droguerre, M | 1 |
| Jo, JK | 1 |
| Lee, G | 1 |
| Nguyen, CD | 1 |
| Park, SE | 1 |
| Kim, EJ | 1 |
| Kim, HW | 1 |
| Seo, SH | 1 |
| Cho, KM | 1 |
| Kwon, SJ | 1 |
| Kim, JH | 1 |
| Son, HS | 1 |
| Nguyen, HD | 1 |
| Kirkman, MA | 3 |
| Day, J | 3 |
| Gehring, K | 4 |
| Zienius, K | 3 |
| Grosshans, D | 3 |
| Taphoorn, M | 3 |
| Brown, PD | 3 |
| Sagaro, GG | 1 |
| Traini, E | 1 |
| Amenta, F | 1 |
| Wunderlich, G | 1 |
| Blahova, Z | 1 |
| Garcia, M | 1 |
| Jessen, F | 1 |
| Elbaz, EM | 1 |
| Essam, RM | 1 |
| Ahmed, KA | 1 |
| Safwat, MH | 1 |
| Diaz-Galvan, P | 1 |
| Lorenzon, G | 1 |
| Mohanty, R | 1 |
| Mårtensson, G | 1 |
| Cavedo, E | 3 |
| Lista, S | 3 |
| Vergallo, A | 1 |
| Kantarci, K | 1 |
| Hampel, H | 3 |
| Dubois, B | 3 |
| Grothe, MJ | 2 |
| Ferreira, D | 1 |
| Westman, E | 1 |
| Li, S | 1 |
| Huo, H | 1 |
| Liu, Y | 1 |
| Zhao, D | 1 |
| Dong, X | 1 |
| Zhang, H | 3 |
| She, L | 1 |
| Sun, J | 1 |
| Xiong, L | 1 |
| Li, A | 1 |
| Li, L | 2 |
| Wu, H | 1 |
| Ren, J | 1 |
| Wang, W | 1 |
| Liang, G | 1 |
| Zhao, X | 2 |
| Ahuja, M | 1 |
| Siddhpuria, S | 1 |
| Karimi, A | 1 |
| Lewis, K | 1 |
| Wong, E | 1 |
| Lee, J | 1 |
| Reppas-Rindlisbacher, C | 1 |
| Sood, E | 1 |
| Gabor, C | 1 |
| Patterson, C | 1 |
| Sun, Y | 2 |
| Wei, YJ | 1 |
| Xing, Y | 1 |
| Shih, CC | 1 |
| Chen, PY | 1 |
| Chen, MF | 1 |
| Lee, TJF | 1 |
| Amidzic, A | 1 |
| Tiro, N | 1 |
| Devanand, DP | 4 |
| Liu, X | 1 |
| Chunga, RE | 2 |
| Cohen, H | 1 |
| Andrews, H | 3 |
| Schofield, PW | 2 |
| Stern, Y | 2 |
| Huey, ED | 2 |
| Choi, J | 1 |
| Pelton, GH | 4 |
| Avgerinos, KI | 1 |
| Vrysis, C | 1 |
| Chaitidis, N | 1 |
| Kolotsiou, K | 1 |
| Myserlis, PG | 1 |
| Kapogiannis, D | 1 |
| Kim, GW | 1 |
| Kim, BC | 1 |
| Park, KS | 1 |
| Jeong, GW | 1 |
| Sawada, H | 2 |
| Oeda, T | 2 |
| Kohsaka, M | 2 |
| Tomita, S | 2 |
| Umemura, A | 2 |
| Park, K | 2 |
| Yamamoto, K | 2 |
| Kiyohara, K | 2 |
| Stær, K | 1 |
| Iranzo, A | 1 |
| Stokholm, MG | 1 |
| Østergaard, K | 1 |
| Serradell, M | 1 |
| Otto, M | 1 |
| Svendsen, KB | 1 |
| Garrido, A | 1 |
| Vilas, D | 1 |
| Santamaria, J | 1 |
| Møller, A | 1 |
| Gaig, C | 1 |
| Brooks, DJ | 1 |
| Borghammer, P | 1 |
| Tolosa, E | 1 |
| Pavese, N | 1 |
| Zhang, Q | 1 |
| Aldridge, GM | 1 |
| Narayanan, NS | 1 |
| Anderson, SW | 1 |
| Uc, EY | 1 |
| Bell, MD | 1 |
| Pittman, B | 1 |
| Petrakis, I | 1 |
| Yoon, G | 1 |
| Murchison, CF | 1 |
| Kennedy, RE | 1 |
| McConathy, JE | 1 |
| Roberson, ED | 1 |
| Zhao, J | 2 |
| Li, K | 1 |
| Li, D | 1 |
| Xie, S | 1 |
| Wang, J | 2 |
| Zuo, Z | 2 |
| D'Onofrio, G | 1 |
| Nabavi, SM | 1 |
| Sancarlo, D | 1 |
| Greco, A | 1 |
| Pieretti, S | 1 |
| Guo, X | 1 |
| Liu, J | 1 |
| Quan, Q | 1 |
| Su, H | 1 |
| Gao, F | 1 |
| Qu, Q | 1 |
| Baik, K | 1 |
| Kim, SM | 1 |
| Jung, JH | 1 |
| Lee, YH | 1 |
| Chung, SJ | 1 |
| Yoo, HS | 1 |
| Ye, BS | 1 |
| Lee, PH | 1 |
| Sohn, YH | 1 |
| Kang, SW | 1 |
| Kang, SY | 1 |
| Tung, EE | 1 |
| Litin, SC | 1 |
| Bundrick, JB | 1 |
| Lentz, C | 1 |
| Ciarleglio, A | 2 |
| Scodes, JM | 1 |
| Bell, K | 1 |
| Shirayama, Y | 1 |
| Takahashi, M | 1 |
| Oda, Y | 1 |
| Yoshino, K | 1 |
| Sato, K | 1 |
| Okubo, T | 1 |
| Iyo, M | 1 |
| Perng, CH | 1 |
| Chang, YC | 1 |
| Tzang, RF | 1 |
| Kaundal, M | 1 |
| Deshmukh, R | 1 |
| Akhtar, M | 1 |
| Motter, JN | 1 |
| D'Antonio, K | 2 |
| Rushia, SN | 1 |
| Pimontel, MA | 1 |
| Petrella, JR | 2 |
| Garcon, E | 1 |
| Ciovacco, MW | 1 |
| Sneed, JR | 1 |
| Doraiswamy, PM | 2 |
| Scodes, J | 1 |
| Lunsford, J | 1 |
| Beyer, JL | 1 |
| Sneed, J | 1 |
| Ciovacco, M | 1 |
| Mizoguchi, K | 1 |
| Matsuo, H | 1 |
| Hasegawa, K | 1 |
| Fujimura, H | 1 |
| Sugiyama, H | 1 |
| Nakamura, M | 1 |
| Kikuchi, S | 1 |
| Fukuda, T | 1 |
| Ito, S | 1 |
| Goto, M | 1 |
| Kawamura, T | 1 |
| Zhang, N | 1 |
| Gordon, ML | 1 |
| Mei, L | 1 |
| Wu, S | 1 |
| Li, H | 1 |
| Wang, M | 1 |
| Shabani, S | 1 |
| Mirshekar, MA | 1 |
| Montero-Odasso, M | 1 |
| Speechley, M | 1 |
| Chertkow, H | 1 |
| Sarquis-Adamson, Y | 1 |
| Wells, J | 1 |
| Borrie, M | 1 |
| Vanderhaeghe, L | 1 |
| Zou, GY | 1 |
| Fraser, S | 1 |
| Bherer, L | 1 |
| Muir-Hunter, SW | 1 |
| Baakman, AC | 1 |
| Zuiker, R | 1 |
| van Gerven, JMA | 1 |
| Gross, N | 1 |
| Yang, R | 1 |
| Fetell, M | 1 |
| Gershon, A | 1 |
| Gilgun-Sherki, Y | 1 |
| Hellriegel, E | 1 |
| Spiegelstein, O | 1 |
| Karschnia, P | 1 |
| Parsons, MW | 1 |
| Dietrich, J | 1 |
| Tseng, WT | 1 |
| Yeh, JY | 1 |
| Lane, HY | 1 |
| Lin, CH | 1 |
| van Lonkhuizen, PJC | 1 |
| Klaver, KM | 1 |
| Wefel, JS | 1 |
| Sitskoorn, MM | 1 |
| Schagen, SB | 1 |
| Ren, T | 1 |
| Yang, M | 1 |
| Pa, J | 1 |
| Berry, AS | 1 |
| Compagnone, M | 1 |
| Boccanfuso, J | 1 |
| Greenhouse, I | 1 |
| Rubens, MT | 1 |
| Johnson, JK | 1 |
| Gazzaley, A | 1 |
| Tricco, AC | 1 |
| Soobiah, C | 1 |
| Berliner, S | 1 |
| Ho, JM | 1 |
| Ng, CH | 1 |
| Ashoor, HM | 1 |
| Chen, MH | 1 |
| Hemmelgarn, B | 1 |
| Straus, SE | 1 |
| Sonali, N | 1 |
| Tripathi, M | 1 |
| Sagar, R | 1 |
| Velpandian, T | 1 |
| Subbiah, V | 1 |
| Diniz, BS | 1 |
| Reynolds, CF | 1 |
| Begley, A | 1 |
| Dew, MA | 1 |
| Anderson, SJ | 1 |
| Lotrich, F | 1 |
| Erickson, KI | 1 |
| Lopez, O | 1 |
| Aizenstein, H | 1 |
| Sibille, EL | 1 |
| Butters, MA | 1 |
| Leung, JG | 1 |
| Shoji, M | 1 |
| Dhanjal, NS | 2 |
| Wise, RJ | 2 |
| Castellino, SM | 1 |
| Ullrich, NJ | 1 |
| Whelen, MJ | 1 |
| Lange, BJ | 1 |
| Donohue, MC | 1 |
| Moghadam, SH | 1 |
| Roe, AD | 1 |
| Sun, CK | 1 |
| Edland, SD | 1 |
| Thomas, RG | 1 |
| Petersen, RC | 1 |
| Sano, M | 1 |
| Galasko, D | 1 |
| Aisen, PS | 2 |
| Ransmayr, G | 1 |
| Papp, M | 1 |
| Gruca, P | 1 |
| Lason-Tyburkiewicz, M | 1 |
| Willner, P | 1 |
| Teipel, SJ | 1 |
| Galluzzi, S | 2 |
| Colliot, O | 2 |
| Chupin, M | 2 |
| Bakardjian, H | 1 |
| Dormont, D | 2 |
| Kucinski, A | 1 |
| de Jong, IE | 1 |
| Sarter, M | 1 |
| De Beaumont, L | 1 |
| Pelleieux, S | 1 |
| Lamarre-Théroux, L | 1 |
| Dea, D | 1 |
| Poirier, J | 1 |
| Croisile, B | 1 |
| Tisserand, GL | 1 |
| Touchon, J | 1 |
| Bonafe, A | 1 |
| Ousset, PJ | 1 |
| Rouaud, O | 1 |
| Ricolfi, F | 1 |
| Vighetto, A | 1 |
| Pasquier, F | 1 |
| Delmaire, C | 1 |
| Ceccaldi, M | 1 |
| Girard, N | 1 |
| Lehericy, S | 1 |
| Duveau, F | 1 |
| Sarazin, M | 1 |
| Sokolow, S | 1 |
| Li, X | 1 |
| Taylor, KD | 1 |
| Rotter, JI | 1 |
| Apostolova, LG | 1 |
| Xu, S | 1 |
| Liu, L | 1 |
| Feng, R | 1 |
| Gong, Y | 1 |
| Cai, J | 1 |
| Feng, N | 1 |
| Wang, L | 1 |
| Peng, Y | 1 |
| Schuff, N | 1 |
| Suhy, J | 1 |
| Goldman, R | 1 |
| Xu, Y | 1 |
| Truran-Sacrey, D | 1 |
| Murthy, A | 1 |
| Browne, G | 1 |
| Berry, E | 1 |
| Kapur, N | 1 |
| Hodges, S | 1 |
| Smyth, G | 1 |
| Watson, P | 1 |
| Wood, K | 1 |
| Amanzio, M | 1 |
| Benedetti, F | 1 |
| Vase, L | 1 |
| Miao, YC | 1 |
| Tian, JZ | 1 |
| Shi, J | 1 |
| Mao, M | 1 |
| Odawara, T | 1 |
| Djalalov, S | 1 |
| Yong, J | 1 |
| Beca, J | 1 |
| Black, S | 1 |
| Saposnik, G | 1 |
| Musa, Z | 1 |
| Siminovitch, K | 1 |
| Moretti, M | 1 |
| Hoch, JS | 1 |
| Konishi, K | 1 |
| Hori, K | 1 |
| Tomioka, H | 1 |
| Minegishi, G | 1 |
| Tani, M | 1 |
| Tanaka, H | 1 |
| Akita, R | 1 |
| Yokoyama, S | 1 |
| Oshio, T | 1 |
| Hachisu, M | 1 |
| Warren, JE | 1 |
| Patel, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficiency of Donepezil in Elderly Patients Undergoing Orthopedic Surgery Due to Underlying Postoperative Cognitive Dysfunction, a Multicenter Randomized Controlled Trial[NCT04423276] | Phase 4 | 360 participants (Anticipated) | Interventional | 2020-06-14 | Recruiting | ||
| Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly[NCT01951118] | Phase 4 | 121 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Dementia Clinical Trials: A Study on the Clinical Trial Participation of Dementia Patients[NCT05850000] | 500 participants (Anticipated) | Observational | 2024-05-31 | Not yet recruiting | |||
| Factors Influencing the Deterioration From Cognitive Decline of Normal Aging to Dementia Among Nursing Home Residents[NCT04589637] | 182 participants (Actual) | Observational | 2018-05-29 | Completed | |||
| Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression[NCT01658228] | Phase 4 | 86 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Can Cognitive Enhancers Reduce the Risk of Falls in Older People With Mild Cognitive Impairment? A Randomized Controled Trial[NCT00934531] | 60 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| Maintenance Therapies in Late-Life Depression: MTLD III[NCT00177671] | Phase 4 | 220 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19[NCT04632719] | 200 participants (Anticipated) | Interventional | 2020-11-08 | Recruiting | |||
| Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias[NCT02921477] | Phase 1 | 150 participants (Anticipated) | Interventional | 2016-09-30 | Enrolling by invitation | ||
| Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders[NCT00403520] | Phase 4 | 240 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Efficacy Study of Yi-Zhi-An-Shen Granules For Older Adults With Amnestic Mild Cognitive Impairment: a Randomized, Double-blind, Placebo-controlled Study[NCT03601000] | Phase 1/Phase 2 | 80 participants (Actual) | Interventional | 2018-04-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The modified Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) is a cognitive battery that assesses learning, memory, language production, language comprehension, constructional praxis, ideational praxis, and orientation. The ADAS-Cog is not a timed test and the participant's score does not depend on how rapidly the test is completed. The ADAS-Cog total score is based on the total number of errors made in the test by the participant. Therefore, a lower total score indicates a higher cognitive performance. The total score ranges from 0 to 95 and is determined by summing the errors from 12 subscales. The total score, indicating number of errors made, is the number that is reported at each timeframe. (NCT01951118)
Timeframe: Week 0, Week 8, Week 26, Week 52
| Intervention | Errors (Mean) | |||
|---|---|---|---|---|
| Week 0 | Week 8 | Week 26 | Week 52 | |
| AD Sample | 21.67 | 19.30 | 19.63 | 22.69 |
| MCI Sample | 11.41 | 10.13 | 9.63 | 10.40 |
The Selective Reminding Test (SRT) is a 12-item test of verbal learning and memory. To administer, the researcher will read aloud a list of 12 words. The participant repeats each word aloud to ensure that the word was heard correctly. Immediately following the reading of all 12 words, the participant is asked to recall as many words as possible within the one minute time limit. The participant is then reminded of the words they did not say and asked to recall the list again. This process is repeated for 6 trials. The total immediate recall is the total number of words recalled by the participant from all 6 trials. This is the number that is reported. Lower scores indicate fewer words recalled and a poorer performance. (NCT01951118)
Timeframe: Week 0, Week 8, Week 26, Week 52
| Intervention | Words (Mean) | |||
|---|---|---|---|---|
| Week 0 | Week 8 | Week 26 | Week 52 | |
| AD Sample | 21.19 | 24.10 | 23.00 | 24.38 |
| MCI Sample | 36.14 | 39.99 | 39.75 | 39.62 |
The CIBIC-plus is a well-validated, reliable and widely used measure (range 1-7) of global improvement used in AD and MCI trials. This is a measure of change based on clinician impression. Higher values represent a worse outcome. (NCT01951118)
Timeframe: Week 8, Week 26, Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Week 8 | Week 26 | Week 52 | |
| AD Sample | 3.55 | 3.75 | 4.38 |
| MCI Sample | 3.34 | 3.15 | 3.11 |
"This instrument has 40 items, takes 20 minutes to administer, and focuses on functional correlates of cognitive deficits. This assessment asks the study informant to rate the participant's ability to perform certain tasks with the domains of Memory, Language, Visual-spatial and Perceptual Abilities, Executive Functioning: Planning, Executive Functioning: Organization, and Executive Functioning: Divided Attention. The informant is asked to compare functioning from 10 years prior to the time of testing. The Everyday Cognition measure uses the sum score of all of the subscales, and the items are reverse coded (i.e., 1= Better or no change, 2=Questionable/occasionally worse, 3=Consistently a little worse, 4=Consistently much worse), meaning that lower scores are better. Reported total scores range from 39 (Better or no change) to 156 (Consistently much worse)." (NCT01951118)
Timeframe: Week 0, Week 8, Week 26, Week 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Week 0 | Week 8 | Week 26 | Week 52 | |
| AD Sample | 90.80 | 89.20 | 97.65 | 103.59 |
| MCI Sample | 67.93 | 67.88 | 67.92 | 66.84 |
The Mini Mental State Examination (MMSE) is a widely used 30-item test of cognitive function that includes tests of orientation, attention, memory, language, and visual-spatial skills. Values range from 0-30; a higher value represents a better outcome. (NCT01951118)
Timeframe: Week 0, Week 26, Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Week 0 | Week 26 | Week 52 | |
| AD Sample | 23.048 | 21.20 | 20.35 |
| MCI Sample | 26.72 | 26.90 | 26.44 |
"FAQ is a widely used 10-item instrument that takes 3 minutes to administer and focuses on instrumental, social and cognitive functioning. The assessment is completed by a study informant - typically a caregiver able to report best on the patient's current ability. The instrument assesses the patient's current ability, at the point of testing and through the past month, in these various domains. The total score is described as the cumulative scores of each item, ranging from 0 - No help needed to 3 - No, unable to do. More impairment is indicated by higher scores. The reported total score range is from 0 (no impairment score) to 30 (maximum impairment score)." (NCT01951118)
Timeframe: Week 0, Week 8, Week 26, Week 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Week 0 | Week 8 | Week 26 | Week 52 | |
| AD Sample | 11.25 | 11.78 | 13.75 | 14.62 |
| MCI Sample | 4.80 | 4.68 | 4.84 | 4.25 |
The Treatment Emergent Symptom Scale (TESS) is widely used to evaluate somatic side effects. For each item, a rating is made on a 3-point scale, with an additional rating on the likelihood that the medication caused the side effect. Values range from 0-78; a higher value indicates a worse outcome. (NCT01951118)
Timeframe: Week 0, Week 8, Week 26, Week 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Week 0 | Week 8 | Week 26 | Week 52 | |
| AD Sample | 1.89 | 1.53 | 1.20 | 1.69 |
| MCI Sample | 2.57 | 1.61 | 1.42 | 1.28 |
The Wechsler Adult Intelligence Scale (WAIS) -III Digit Symbol Subtest is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. Values range from 0-93; a higher value represents a better outcome. (NCT01951118)
Timeframe: Week 0, Week 52
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 0 | Week 52 | |
| AD Sample | 25.47 | 21.06 |
| MCI Sample | 36.83 | 37.24 |
The modified ADAS-Cog is a cognitive battery that assesses learning, memory, language production, language comprehension, constructional praxis, ideational praxis, and orientation. Subjects' scores represent the total number of errors made throughout the various tasks. The total number of possible errors is between 0-85. (NCT01658228)
Timeframe: Week 16
| Intervention | number of errors on a scale from 0-85 (Mean) |
|---|---|
| Donepezil Treatment Group | 13.2 |
| Placebo Treatment Group | 13.9 |
The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) and delayed recall (after a 15-minute delay) was obtained. (NCT01658228)
Timeframe: Week 16
| Intervention | Words (Mean) |
|---|---|
| Donepezil Treatment Group | 7.4 |
| Placebo Treatment Group | 7.4 |
The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) was obtained. (NCT01658228)
Timeframe: Week 16
| Intervention | Words (Mean) |
|---|---|
| Donepezil Treatment Group | 45.6 |
| Placebo Treatment Group | 46.6 |
Recurrence of major depressive episodes as determined by SCID/DSM IV: two weeks of low mood and/or anhedonia, together with at least five of the following symptoms: suicidal ideation, low energy, sleep disturbance, appetite disturbance, psychic anxiety or somatic anxiety. In addition, a diagnosis of major depression requires evidence of distress or impairment. (NCT00177671)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Donepezil | 19 |
| Placebo | 11 |
Conversion to dementia was ascertained by the University of Pittsburgh Alzheimer Disease Research Center (ADRC), using data on neuropsychological performance and IADL functioning, as well as other relevant clinical data. Diagnoses were made according to National Alzheimer Coordinating Center criteria. (NCT00177671)
Timeframe: 2 year
| Intervention | Percent of Participants (Number) |
|---|---|
| Donepezil | 10 |
| Placebo | 33 |
The PASS (a performance-based assessment of instrumental activities of daily living)generates a composite measure of 13 cognitive IADL items capturing performance on activities such as shopping, bill paying, medication management, and home safety. We report the percentage of subjects at each assessment point adjudged to have independent functioning. This was determined by a clinician rater observing subjects perform each task and rating them according to predetermined criteria on a 4 point scale, ranging from 0 (unable) to 3 (independent). (NCT00177671)
Timeframe: baseline, year 1 and year 2
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Baseline (N=33; N=34) | Year 1 (N=23; N=25) | Year 2 (N=11; N=17) | |
| Donepezil | 54.10 | 62.16 | 36.67 |
| Placebo | 61.82 | 54.35 | 47.22 |
Cognitive performance was assessed with 17 well established and validated individual tests measuring multiple domains. We transformed raw scores for individual tests into Z-scores using the baseline distribution of a non-depressed, cognitively normal, older adult comparison group (N=36)of similar age, education, and medical health recruited concurrently with the depressed participants. These Z-scores were averaged within each neuropsychological area to produce domain scores and then averaged over all 17 tests to calculate a global cognition performance score. (NCT00177671)
Timeframe: Measured at baseline and Years 1 and 2 in maintenance
| Intervention | Z-score (Mean) | ||
|---|---|---|---|
| Baseline (N=67;N=63) | Year 1 (N=45; N=57) | Year 2 N=42; N=49) | |
| Donepezil | -0.47 | -0.23 | -0.31 |
| Placebo | -0.47 | -0.65 | -0.56 |
19 reviews available for donepezil and Cognitive Decline
| Article | Year |
|---|---|
A meta-analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Exercise; Humans; Ra | 2021 |
Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; | 2022 |
Efficacy and safety of donepezil for mild cognitive impairment: A systematic review and meta-analysis.
Topics: Cognition; Cognitive Dysfunction; Databases, Factual; Donepezil; Humans; Nootropic Agents; Randomize | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.
Topics: Cognition; Cognition Disorders; Cognitive Dysfunction; Donepezil; Glycerylphosphorylcholine; Humans; | 2023 |
The efficacy of acupuncture combined with other therapies in post stroke cognitive impairment: A network meta-analysis.
Topics: Acupuncture Therapy; Cognitive Dysfunction; Donepezil; Humans; Network Meta-Analysis; Stroke | 2023 |
Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis.
Topics: Accidental Falls; Accidental Injuries; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; | 2023 |
Effects of saffron (Crocus sativus L.) on cognitive function. A systematic review of RCTs.
Topics: Alzheimer Disease; Cognition; Cognitive Dysfunction; Crocus; Donepezil; Humans | 2020 |
Approach to Cognitive Impairment in Parkinson's Disease.
Topics: Arousal; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Executive Function; Humans; Me | 2020 |
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Crocus; Donepezil; Humans; Memantine | 2021 |
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis.
Topics: Alzheimer Disease; Clinical Trials as Topic; Cognitive Dysfunction; Combined Modality Therapy; Compl | 2018 |
Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients.
Topics: Alzheimer Disease; China; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Meman | 2018 |
Pharmacologic management of cognitive impairment induced by cancer therapy.
Topics: Antineoplastic Agents; Central Nervous System Stimulants; Cholinesterase Inhibitors; Cognitive Dysfu | 2019 |
Interventions for cognitive problems in adults with brain cancer: A narrative review.
Topics: Brain Neoplasms; Central Nervous System Stimulants; Cholinesterase Inhibitors; Cognition; Cognitive | 2019 |
Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; Indans; Memantine; | 2013 |
[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Cognitive Dysfuncti | 2014 |
Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors.
Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Attention; Benzhydryl Compounds; Br | 2014 |
Cognitive impairment in Parkinson's disease.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Memantine; Muscle Rigidity; Par | 2015 |
A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment.
Topics: Aged; Alzheimer Disease; Cognitive Dysfunction; Donepezil; Humans; Indans; Nootropic Agents; Piperid | 2012 |
22 trials available for donepezil and Cognitive Decline
| Article | Year |
|---|---|
Efficiency of donepezil in elderly patients undergoing orthopaedic surgery due to underlying post-operative cognitive dysfunction: study protocol for a multicentre randomised controlled trial.
Topics: Acetylcholinesterase; Aged; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Mul | 2021 |
Modulation of Amyloid-β and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cognitive Dysfunction; Donepezil; Extracellula | 2022 |
A single-center, randomized, parallel design study to evaluate the efficacy of donepezil in improving visuospatial abilities in patients with mild cognitive impairment using eye-tracker: the COG-EYE study protocol for a phase II trial.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase II | 2022 |
Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer's dementia: a randomized controlled trial.
Topics: Aged; Alzheimer Disease; Cognitive Dysfunction; Donepezil; Double-Blind Method; Female; Humans; Male | 2023 |
Differential response to donepezil in MRI subtypes of mild cognitive impairment.
Topics: Alzheimer Disease; Atrophy; Cognitive Dysfunction; Donepezil; Humans; Magnetic Resonance Imaging | 2023 |
Early-start
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Double-Blind Method; | 2021 |
Donepezil and cognitive remediation therapy to augment treatment of alcohol use disorder related mild cognitive impairment (AUD-MCI): An open label pilot study with historical controls.
Topics: Alcoholism; Cognitive Dysfunction; Cognitive Remediation; Donepezil; Humans; Male; Pilot Projects | 2021 |
Clinical and radiological characteristics of early versus late mild cognitive impairment in patients with comorbid depressive disorder.
Topics: Age of Onset; Aged; Aged, 80 and over; Antidepressive Agents; Cholinesterase Inhibitors; Cognitive D | 2018 |
Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cholinesterase Inhibitors; Cognit | 2018 |
Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cholinesterase Inhibitors; Cognit | 2018 |
Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cholinesterase Inhibitors; Cognit | 2018 |
Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cholinesterase Inhibitors; Cognit | 2018 |
Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: a randomised controlled trial for 2 years.
Topics: Aged; Aged, 80 and over; Apolipoprotein E4; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepe | 2018 |
Donepezil for gait and falls in mild cognitive impairment: a randomized controlled trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Cognition; Cognitive Dysfunction; Donepezil; Double-Blind | 2019 |
Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.
Topics: Adolescent; Adult; Brain; Cognition; Cognitive Dysfunction; Cohort Studies; Cross-Over Studies; Done | 2019 |
Cholinergic enhancement of functional networks in older adults with mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Brain; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Double- | 2013 |
Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: a longitudinal study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cognitive Dysfunc | 2014 |
Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Biomarkers; Blood Chemical Analys | 2015 |
[Nourishing Xin and Shen method improved mild cognitive impairment due to subcortical small vessel disease: a clinical study].
Topics: Alzheimer Disease; Biomedical Research; Cognition; Cognitive Dysfunction; Dementia; Donepezil; Drugs | 2015 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
Topics: Age of Onset; Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E4; Butyrylcholinesterase; | 2016 |
Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Cerebral Cortex; Cognitive Dysfunction; Disease | 2016 |
An MRI substudy of a donepezil clinical trial in mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Brain; Cognitive Dysfunction; Donepezil; Double-Blind Method; Female; Human | 2011 |
Effects of Chinese medicine for tonifying the kidney and resolving phlegm and blood stasis in treating patients with amnestic mild cognitive impairment: a randomized, double-blind and parallel-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Donepezil; Double-Blind Me | 2012 |
Auditory cortical function during verbal episodic memory encoding in Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Attention; Auditory Cortex; Auditory Perceptual D | 2013 |
53 other studies available for donepezil and Cognitive Decline
| Article | Year |
|---|---|
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Design, synthesis and pharmacological evaluation of some novel indanone derivatives as acetylcholinesterase inhibitors for the management of cognitive dysfunction.
Topics: Acetylcholinesterase; Animals; Avoidance Learning; Cholinesterase Inhibitors; Cognitive Dysfunction; | 2018 |
Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species.
Topics: Acetic Acid; Animals; Catalytic Domain; Cognitive Dysfunction; Cyclic Nucleotide Phosphodiesterases, | 2018 |
Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Bloo | 2019 |
Design and development of novel N-(pyrimidin-2-yl)-1,3,4-oxadiazole hybrids to treat cognitive dysfunctions.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors; Cognitiv | 2019 |
2-Aminoimidazole-based antagonists of the 5-HT
Topics: Animals; Cells, Cultured; Cognitive Dysfunction; Dose-Response Relationship, Drug; Drug Design; HEK2 | 2019 |
Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antioxidants | 2019 |
Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinergic Antagonists; Cognitive Dysfunction; Cyclic Nucleotide Phosph | 2020 |
Design, synthesis and biological evaluation of novel naturally-inspired multifunctional molecules for the management of Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Animals; Antioxidants; Biological Pro | 2020 |
Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection.
Topics: Amyloid beta-Peptides; Animals; Binding Sites; Butyrylcholinesterase; Cell Survival; Cholinesterase | 2021 |
The Effect of Donepezil on Problem-solving Ability in Individuals With Amnestic Mild Cognitive Impairment: A Pilot Study.
Topics: Cognitive Dysfunction; Donepezil; Humans; Pilot Projects | 2021 |
A Nationwide Multi-Center Questionnaire Survey on the Real-World State and Clinical Management of Poststroke Dementia in Japan.
Topics: Aged; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Donepezil; Female; Galantamine; Huma | 2021 |
Mild Cognitive Impairment and Donepezil Impact Mitochondrial Respiratory Capacity in Skeletal Muscle.
Topics: Aged; Alzheimer Disease; Cognitive Dysfunction; Donepezil; Humans; Mitochondria; Muscle, Skeletal | 2021 |
Donepezil improves vascular function in a mouse model of Alzheimer's disease.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cardiovascular Diseases; Cholinesterase Inhibitors; Cogni | 2021 |
Association between long-term donepezil treatment and brain regional amyloid and tau burden among individuals with mild cognitive impairment assessed using
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Carbolines; Cognitive Dysfunction; Donepezil; Human | 2022 |
Cognitive impairment networks in Alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Cognitive Dysfunction; | 2022 |
Can the Energetic Profile of Skeletal Muscle Predict Risk of Cognitive Impairment?
Topics: Cognitive Dysfunction; Donepezil; Humans; Mitochondria; Muscle, Skeletal | 2021 |
6-Methoxyflavone and Donepezil Behavioral Plus Neurochemical Correlates in Reversing Chronic Ethanol and Withdrawal Induced Cognitive Impairment.
Topics: Animals; Ascorbic Acid; Cognitive Dysfunction; Donepezil; Dopamine; Ethanol; Flavones; Hippocampus; | 2022 |
Effectiveness of an integrative medicine approach to improve cognitive dysfunction and dementia: An observational study.
Topics: Anticonvulsants; Cognition; Cognitive Dysfunction; Dementia; Donepezil; Humans; Integrative Medicine | 2022 |
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cognitive Dysfunction; Donepezil; Humans; Indans; | 2022 |
Effects of Donepezil Treatment on Brain Metabolites, Gut Microbiota, and Gut Metabolites in an Amyloid Beta-Induced Cognitive Impairment Mouse Pilot Model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognitive Dysfunction; Disease Models, Ani | 2022 |
Combination of Donepezil and Memantine Attenuated Cognitive Impairment Induced by Mixed Endocrine-Disrupting Chemicals: an In Silico Study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Indans; Mema | 2022 |
Donepezil halts acetic acid-induced experimental colitis in rats and its associated cognitive impairment through regulating inflammatory/oxidative/apoptotic cascades: An add-on to its anti-dementia activity.
Topics: Acetic Acid; Acetylcholinesterase; Animals; Antioxidants; Cognitive Dysfunction; Colitis; Colitis, U | 2023 |
Ginsenoside RK1 improves cognitive impairments and pathological changes in Alzheimer's disease via stimulation of the AMPK/Nrf2 signaling pathway.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Animals; Cognitive Dysfunction; Donepezil; NF-E2-R | 2024 |
Vascular cognitive impairment associated with NOTCH3 Exon 33 mutation: A case report.
Topics: Cognitive Dysfunction; Dementia, Vascular; Donepezil; Humans; Male; Memantine; Middle Aged; Mutation | 2019 |
Differential blockade by huperzine A and donepezil of sympathetic nicotinic acetylcholine receptor-mediated nitrergic neurogenic dilations in porcine basilar arteries.
Topics: Alkaloids; Alzheimer Disease; Animals; Basilar Artery; Brain Stem; Calcium; Cholinesterase Inhibitor | 2020 |
Kinking of Bilateral Internal Carotid Arteries as Cause of Cognitive Dysfunction.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Bosnia and Herzegovina; Bromazepam; Carotid Artery, | 2020 |
Odor Identification Impairment and Change with Cholinesterase Inhibitor Treatment in Mild Cognitive Impairment.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Female; Humans | 2020 |
A pilot study of brain morphometry following donepezil treatment in mild cognitive impairment: volume changes of cortical/subcortical regions and hippocampal subfields.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebral Cortex; Cognitive Dysfunction; Disease P | 2020 |
Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder.
Topics: Acetylcholinesterase; Aged; Carbon Radioisotopes; Cerebral Cortex; Cholinesterase Inhibitors; Cognit | 2020 |
Racial Differences in Alzheimer's Disease Specialist Encounters Are Associated with Usage of Molecular Imaging and Dementia Medications: An Enterprise-Wide Analysis Using i2b2.
Topics: Academic Medical Centers; Aged; Alzheimer Disease; Black or African American; Cholinesterase Inhibit | 2021 |
Enhanced anti-amnestic effect of donepezil by Ginkgo biloba extract (EGb 761) via further improvement in pro-cholinergic and antioxidative activities.
Topics: Acetylcholinesterase; Amnesia; Animals; Antioxidants; Behavior, Animal; Brain; Cell Line; Cholinergi | 2021 |
Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Benzofurans; Cognitive Dysfu | 2021 |
Donepezil for mild cognitive impairment in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognitive Dysfunction; Disease Progressio | 2021 |
Clinical Pearls in Geriatrics.
Topics: Acetaminophen; Aged; Aged, 80 and over; Automobile Driving; Cognition Disorders; Cognitive Dysfuncti | 2017 |
Change in Odor Identification Impairment is Associated with Improvement with Cholinesterase Inhibitor Treatment in Mild Cognitive Impairment.
Topics: Aged; Atropine; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Female; Humans; Indans; | 2017 |
rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine.
Topics: Aged; Alzheimer Disease; Brain; Brain Mapping; Cerebrovascular Circulation; Cholinesterase Inhibitor | 2019 |
Protective effect of betulinic acid against intracerebroventricular streptozotocin induced cognitive impairment and neuronal damage in rats: Possible neurotransmitters and neuroinflammatory mechanism.
Topics: Acetylcholinesterase; Animals; Betulinic Acid; Cognitive Dysfunction; Disease Models, Animal; Donepe | 2018 |
Epidemiology of Dementia in Elderly Chronic Obstructive Pulmonary Disease Patients Living in China's Northwestern High-Elevation Area.
Topics: Acetylcholinesterase; Activities of Daily Living; Aged; Aged, 80 and over; Altitude; Asian People; C | 2018 |
Diosmin is neuroprotective in a rat model of scopolamine-induced cognitive impairment.
Topics: Animals; Cognitive Dysfunction; Diosmin; Disease Models, Animal; Donepezil; Hippocampus; Long-Term P | 2018 |
Effects of donepezil on cognition and global functioning in patients with delayed encephalopathy after carbon monoxide poisoning: A case series.
Topics: Adult; Behavioral Symptoms; Brain Diseases; Carbon Monoxide Poisoning; Cholinesterase Inhibitors; Co | 2019 |
Reduced systemic exposure and brain uptake of donepezil in rats with scopolamine-induced cognitive impairment.
Topics: Animals; Brain; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Rats; Scopolamine | 2020 |
Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.
Topics: Aged; Alleles; Alzheimer Disease; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; C | 2014 |
Donepezil-induced mania.
Topics: Aged; Bipolar Disorder; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Indans; | 2014 |
Frontoparietal cognitive control of verbal memory recall in Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; | 2014 |
Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Cholinesterase Inhibitors; Cognitive Dysfunction; Depress | 2016 |
Reducing falls in Parkinson's disease: interactions between donepezil and the 5-HT
Topics: Animals; Benzylamines; Cholinesterase Inhibitors; Cognition; Cognitive Dysfunction; Corpus Striatum; | 2017 |
Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.
Topics: Aged; Aged, 80 and over; Apolipoprotein E4; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognit | 2017 |
Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Brain; Cell Line, Tumor; Cholinestera | 2017 |
SenseCam improves memory for recent events and quality of life in a patient with memory retrieval difficulties.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Cues; Donepezil; Environmental Monitoring; Female; | 2011 |
Cautious notification and continual monitoring of patients with mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Combin | 2012 |
Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine.
Topics: Aged; Aged, 80 and over; Amnesia; Canada; Case-Control Studies; Chemoprevention; Cognitive Dysfuncti | 2012 |
Donepezil abolishes anticholinergic activity in a patient with amnesia.
Topics: Aged; Amnesia; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Female; Humans; Indans; | 2013 |